<DOC>
	<DOCNO>NCT02221154</DOCNO>
	<brief_summary>The original mechanism action myo-inositol preliminary result available literature use IVF suggest value adjuvant gonadotropin therapy reduce risk OHSS PCOS patient . The aim study demonstrate administration myo-inositol decrease incidence ovarian hyperstimulation syndrome ( OHSS ) high-risk infertile PCOS support IVF patient .</brief_summary>
	<brief_title>Use Myo-inositol Adjuvant Therapy Patients With Polycystic Ovary Syndrome ( PCOS ) Vitro Fertilization ( IVF )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Inositol</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Patients PCOS ( Rotterdam ESHRE / ASRM criterion ) Combination least two follow three criterion : Cycle disorder Clinical hyperandrogenism / biological Account antral follicle &gt; 24 Age ≤ 18 ≤ 38 year BMI &lt; 35 kg / m² Able understand protocol sign informed consent Patients Rotterdam criterion Patients &gt; 38 year / BMI &gt; 35 kg / m² Woman enjoy measure legal protection Hypersensitivity component Inofolic ( myoinositol , soy , folic acid , glycerol , gelatin , color E171 ) Participation another interventional biomedical research treatment administer may disrupt ovarian stimulation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>38 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>vitro fertilization</keyword>
	<keyword>ovarian hyperstimulation</keyword>
	<keyword>pregnancy</keyword>
</DOC>